Joseph is a project editor covering healthcare and life science markets around the world. He holds a BSc in International Marketing from Rowan University and a MSc in Healthcare Innovation from Copenhagen Business School. Joseph is particularly interested in commercial marketing strategy, public-private partnership, and the cross-functional engagement of healthcare stakeholders.
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist…
Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland China, in 2016 Taiwan’s government introduced the New Southbound Policy (NSP).…
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which are sparking global interest and attention – iXensor being a chief example. The company’s patented technology…
As Thailand’s focus has shifted towards R&D over the past few years, the number of in-country clinical trials being conducted has increased concurrently. From 2011 to 2016, Thailand conducted a…
Taiwan has long been a leader in biotechnology research and development. With the government’s emphasis on higher education and research, Taiwan has trained a diverse pool of talent in the…
See our Cookie Privacy Policy Here
